Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study.

IF 4.8 3区医学 Q1 IMMUNOLOGY

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-03-10 DOI:10.1080/14760584.2026.2641671

Maria João Fonseca, Stanislava Bratković, Yunus Çolak, Marie Helleberg, Jørgen Vestbo, Sara Burns, Maria Spanggaard, Kasper Løwe Lundgren, Foteini Gkalapi, Katherine Theiss-Nyland

{"title":"Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study.","authors":"Maria João Fonseca, Stanislava Bratković, Yunus Çolak, Marie Helleberg, Jørgen Vestbo, Sara Burns, Maria Spanggaard, Kasper Løwe Lundgren, Foteini Gkalapi, Katherine Theiss-Nyland","doi":"10.1080/14760584.2026.2641671","DOIUrl":null,"url":null,"abstract":"Background: Individuals with chronic obstructive pulmonary disease (COPD) face increased risk of severe respiratory syncytial virus (RSV)-related outcomes. We assessed the uptake of adjuvanted-RSVPreF3 and its effectiveness against RSV hospitalization in such individuals.Research design and methods: We assembled a Danish nationwide cohort of individuals aged ≥ 60 years with COPD during the 2024/25 RSV season. Vaccinated and unvaccinated individuals were matched using exact and propensity score matching resulting in balanced groups. Individuals were followed from 21 days post-vaccination until the earliest of event, end of data availability, migration, RSV vaccination, or death. Vaccine effectiveness was estimated as (1 - incidence rate ratio [IRR]) x 100, where IRRs were calculated using observed event counts and accumulated person-time. Confidence intervals (CIs) were based on Poisson distributions.Results: Among 126,249 eligible individuals, 7,448 (5.9%) received adjuvanted-RSVPreF3. RSV hospitalization rates per 100,000 person-years were 0.0 (95% CI: 0.0-58.0) for vaccinated individuals and 200.6 (165.6 - 240.8) for unvaccinated individuals, yielding an effectiveness of 100.0% (71.1-100.0). Incidences of other RSV-related outcomes were lower among vaccinated individuals.Conclusions: Adjuvanted-RSVPreF3 is highly effective in preventing RSV hospitalization in individuals aged ≥60 years with COPD. Disease outcomes could be improved by incorporating RSV vaccination into routine COPD management.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2641671"},"PeriodicalIF":4.8000,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2026.2641671","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Individuals with chronic obstructive pulmonary disease (COPD) face increased risk of severe respiratory syncytial virus (RSV)-related outcomes. We assessed the uptake of adjuvanted-RSVPreF3 and its effectiveness against RSV hospitalization in such individuals.

Research design and methods: We assembled a Danish nationwide cohort of individuals aged ≥ 60 years with COPD during the 2024/25 RSV season. Vaccinated and unvaccinated individuals were matched using exact and propensity score matching resulting in balanced groups. Individuals were followed from 21 days post-vaccination until the earliest of event, end of data availability, migration, RSV vaccination, or death. Vaccine effectiveness was estimated as (1 - incidence rate ratio [IRR]) x 100, where IRRs were calculated using observed event counts and accumulated person-time. Confidence intervals (CIs) were based on Poisson distributions.

Results: Among 126,249 eligible individuals, 7,448 (5.9%) received adjuvanted-RSVPreF3. RSV hospitalization rates per 100,000 person-years were 0.0 (95% CI: 0.0-58.0) for vaccinated individuals and 200.6 (165.6 - 240.8) for unvaccinated individuals, yielding an effectiveness of 100.0% (71.1-100.0). Incidences of other RSV-related outcomes were lower among vaccinated individuals.

Conclusions: Adjuvanted-RSVPreF3 is highly effective in preventing RSV hospitalization in individuals aged ≥60 years with COPD. Disease outcomes could be improved by incorporating RSV vaccination into routine COPD management.

查看原文本刊更多论文

佐剂rsvpref3疫苗在COPD患者中的吸收和有效性：一项丹麦全国队列研究

背景：慢性阻塞性肺疾病（COPD）患者面临严重呼吸道合胞病毒（RSV）相关结局的风险增加。我们评估了佐剂rsvpref3疫苗在这些个体中的吸收情况及其对RSV住院的有效性。研究设计和方法：我们收集了丹麦全国范围内年龄≥60岁的COPD患者，这些患者在2024/25 RSV流行季节。接种疫苗和未接种疫苗的个体使用精确和倾向评分匹配匹配，结果平衡组。个体从指数日期（接种疫苗）后21天开始随访，直到最早的事件、数据可用性结束（2025年8月27日）、迁移、接受RSV疫苗或死亡。疫苗有效性估计为（1 -发病率比[IRR]） × 100，其中IRR是通过观察到的事件计数和累积的人时间来计算的。置信区间（ci）基于泊松分布。结果：在126249名符合条件的个体中，7448名（5.9%）接种了rsvpref3佐剂疫苗。接种疫苗的个体每10万人年RSV住院率为0.0 (95% CI: 0.0 - 58.0)，未接种疫苗的个体为200.6(165.6 - 240.8)，有效率为100.0%（71.1 - 100.0）。在接种疫苗的个体中，其他rsv相关结果的发生率较低。结论：佐剂rsvpref3在预防年龄≥60岁COPD患者RSV住院方面非常有效。将RSV疫苗接种纳入常规COPD管理可改善疾病结局。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.